Aims: The purpose of this study was to investigate the association of methylation in the promoter regions of adenomatous polyposis coli (APC) and O 6 -methylguanine-DNA methyltransferase (MGMT) and the survival of Taiwanese colorectal cancer (CRC) subjects who received 5-fluorouracil (5-FU) adjuvant chemotherapy. Results: DNA isolated from tumor tissue of 117 CRC subjects was analyzed for the existence of methylation in the promoter regions of APC and MGMT by methylation-specific PCR. Various characteristics of the 117 subjects were recorded and used in the Cox proportional-hazard model analyses. Methylation in the promoter region is 62.4% (73=117) for APC and 60.7% (71=117) for MGMT in our CRC patients. Subjects presenting methylation in the APC promoter demonstrate significantly lower hazards for all causes of death (hazard ratios ¼ 0.378, p ¼ 0.011) or CRC deaths (hazard ratios ¼ 0.426, p ¼ 0.039). However, no significant correlation is found between the methylation of MGMT promoter and the prognosis of CRC subjects. In addition, no interaction between 5-FU adjuvant chemotherapy and methylation of the two genes are observed. Conclusions: Methylation in the APC promoter may serve as a predictor for the prognosis of Taiwanese CRC patients.
Introduction

D
uring the past three decades, colorectal cancer (CRC) has become particularly prevalent in developed countries. CRC is currently the third most important cause of death due to cancer in the United States ( Jemal et al., 2008) , and the second in Taiwan (Department of Health Executive Yuan, R. O.C., 2008) . Approximately 10% of all CRC is attributed to genetic alterations, whereas 90% occurs sporadically (Weitz et al., 2005) . Sporadic CRC has been shown to correlate with the occurrence of genetic and epigenetic changes such as regional DNA hypermethylation and overall DNA hypomethylation (Feinberg et al., 1988) . Among them, genetic alterations in adenomatous polyposis coli (APC) gene have been reported to play a crucial role in CRC tumor development. Germline mutation of APC primarily causes familial adenomatous polyposis; however, somatic mutations of APC are also found in over 80% of the sporadic colorectal adenoma or carcinoma (Miyoshi et al., 1992) .
The primary treatment of CRC is surgery and often supplemented by chemotherapy and=or radiotherapy. Fivefluorouracil (5-FU), a fluorinated pyrimidine analog, has been widely used in adjuvant chemotherapy for advanced CRC. However, the prognosis of CRC patients and the correlation between epigenetic changes in 5-FU adjuvant chemotherapy remain controversial (de Vos tot Nederveen Cappel et al., 2004; Crozier et al., 2006; Hasegawa et al., 2006) . On the other hand, a relatively higher frequency of APC (germline or somatic) mutations in sporadic CRC has been reported in other ethnic groups (Esteller et al., 2000; Fearnhead et al., 2001; Kámory et al., 2008) . However, a lower germline APC mutation frequency in Taiwanese CRC patients is relatively unique (Chen et al., 2006) . These phenomena have led us to investigate the role of other epigenetic factors in Taiwanese CRC, and their probable role in CRC tumorigenesis and  progression.  O   6 -methylguanine-DNA methyltransferase (MGMT) is responsible for repairing DNA damage caused by alkylating agents. Esteller et al. (2001b) have shown that methylation in the promoter region MGMT may be involved in colorectal tumorigenesis. Nagasaka et al. (2003) also have demonstrated that methylation in the promoter region of MGMT could serve as a predictor of nonrecurrence in CRC patients receiving chemotherapy. Iacopetta (2006) further reported that methylation in the promoter region of MGMT may affect the response of CRC to 5-FU through methyl-group metabolism. However, it is not yet clear whether methylation in the promoter region of MGMT is related to the survival of CRC patients.
Thus, we plan to detect the methylation in the promoter regions of APC and MGMT in Taiwanese CRC subjects to investigate their relationships with 5-FU adjuvant chemotherapy and its prognosis.
Materials and Methods
Subjects
We studied 117 subjects who were diagnosed as CRC and underwent surgical excision at the Tri-Service General Hospital between January 1, 2001, and December 31, 2004. The survival of these subjects was calculated as the time from the date of diagnosis to the date of death or end of follow-up ( July 31, 2006) . The histological diagnosis for CRC was made by two certified anatomical pathology specialists at the Department of Pathology, Tri-Service General Hospital. Colorectal tumor tissues were obtained by surgery of the 117 CRC subjects. Some of the subjects received 5-FU adjuvant chemotherapy (5-FU, 600 mg=m 2 , within 22 h in 2 consecutive days; combined leukovoren, 200 mg=m 2 , within 2 h in 2 consecutive days). This treatment was performed once every 2 weeks and lasted for 8 months. Radiotherapy (4500 cGy; 25 fractions) was also performed in certain subjects dependent on their conditions and preferences. Subjects who received 5-FU adjuvant chemotherapy performed before surgery or within 2 weeks after surgery were recruited in this study. The gender, age of diagnosis, cancer stage (Dukes-Kirklin classification), tumor differentiation, chemotherapy, and radiotherapy history were recorded for all the 117 subjects (Table 1) . Written informed consent was obtained from all subjects who participated in this study, and the study protocol was approved by The Protection of Human Subjects Institutional Review Board, Tzu-Chi University and Hospital.
DNA extraction
Genomic DNA was extracted from *50 mg of colorectal tumor tissue using the Puregene Genomic DNA Purification Kit (Gentra Systems, Minneapolis, MN). The extracted DNA was quantified spectrophotometrically (DU 640; Beckman Instruments, Fullerton, CA) before subjecting to further analysis.
Methylation-specific PCR
Methylation in the promoter regions of APC and MGMT was determined by methylation-specific PCR. In brief, genomic DNA was modified by bisulfite-mediated conversion of unmethylated cytosines using the EpiTect Bisulfite Kit (QIA-GEN, Hilden, Germany). The modified genomic DNA was amplified using primer sets designed specifically for the promoters of APC (Esteller et al., 2000) and MGMT (Chan et al., 2002) , respectively. All samples were amplified in a 30-mL reaction volume containing 50 ng genomic DNA, 10 mM TrisHCl, 50 mM KCl, 2.5 mM MgCl 2 , 0.2 mM of each dNTP, 200 mM of each primer, and 0.2 U AmpliTaq Gold DNA polymerase (Applied Biosystems-Roche Molecular Systems, Branchburg, NJ). The thermal cycle profile was set as follows: initial denaturation at 958C for 10 min, 40 cycles of 30 s denaturation at 958C, 45 s annealing at 568C, and 45 s extension at 728C, followed by a final 10 min extension at 728C at the end of the cycle. PCR products were separated on 3% NuSieve Agarose (3:1) gels (Cambrex Bio Science Rockland, Rockland, ME), stained with ethidium bromide, and visualized by UV transillumination.
Statistical analysis
Spearman correlations were used to analyze the correlation between factors, including gender, age of diagnosis, cancer stage, tumor differentiation, tumor location, and methylation in the promoter regions of APC and MGMT, respectively. We also performed the multivariate analysis with the Cox proportional-hazard model to assess the effects of gender, age of diagnosis, cancer stage, chemotherapy, radiotherapy, and methylation in the promoter regions of APC and MGMT, respectively, on the survival rate of the subjects. The cancer and tumor differentiation stage were transformed into numeral scores to facilitate the Spearman correlations and Cox proportional-hazard model analyses using the following rules: for cancer stage, Dukes A ¼ 0, Dukes B ¼ 1, Dukes C ¼ 2, and Dukes D ¼ 3; for tumor differentiation, well ¼ 0, Nine subjects were omitted due to the lack of differentiation data. Eighteen subjects were omitted due to the lack of tumor location data.
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moderate ¼ 1, and poor ¼ 2; and for tumor location, proximal ¼ 0, distal ¼ 1, and rectal ¼ 2. All tests were two tailed, and data sets were considered to be statistically significant when p < 0.05. Statistical tests were performed using the SPSS 10.0.1 software (Cary, NC).
Results
APC and MGMT promoter methylation
Methylation in the promoter region of MGMT was detected in 60.7% (n ¼ 71=117) of the subjects, which is relatively higher than that in other studies (40-50% in Esteller et al., 2001a and 2001b; Qi et al., 2005; Shen et al., 2005) . Methylation in the promoter region of APC was detected in 62.4% (73=117) of the subjects, which is also higher than that in other studies (18-39% in Esteller et al., 2000; van Engeland et al., 2003; Arnold et al., 2004; Chen et al., 2005) . Further, for the variables analyzed with Spearman correlation, the only significant correlation among the various variables is between the cancer stage and tumor differentiation (Table 2) . Thus, the tumor differentiation variable was excluded during the following Cox proportional-hazard model analysis (Table 3 ). The tumor location variable was also excluded during the following Cox proportional-hazard model analysis due to the lack of the relevant information (Table 1) .
Survival analysis
To better understand how gender, age of diagnosis, cancer stage, chemotherapy, radiotherapy, and methylation in the promoter regions of APC and MGMT could affect the survival rate of CRC subjects, the Cox proportional-hazard model for multivariable analysis was processed. The result indicated that the cancer stage significantly enhanced the subjects' hazards ( p < 0.001; Table 3 ), but 5-FU adjuvant chemotherapy protected subjects from all causes of death ( p ¼ 0.058). Subjects harboring methylation in the promoter region of APC demonstrated significantly lower hazards for all causes of death (hazard ratios ¼ 0.378, p ¼ 0.011) or CRC death (hazard ratios ¼ 0.426, p ¼ 0.039). However, methylation in the promoter region of MGMT and other parameters evaluated in this study did not affect the survival rate of CRC subjects (Table 3) .
To further investigate the interaction between chemotherapy and mutations or methylation in the promoter region of APC or MGMT to the survival of CRC subjects, APC promoter's methylation plus chemotherapy variable (vs. no APC promoter's methylation or no chemotherapy) and MGMT promoter's methylation plus chemotherapy variable (vs. no MGMT promoter's methylation or no chemotherapy) were added to the multivariable Cox proportional-hazard model. The results revealed no significant interaction between chemotherapy and methylation in the promoter regions of APC or MGMT to the survival of CRC subjects.
Discussion
Multivariable Cox proportional-hazard model analysis showed that subjects with methylation in the promoter region of APC have lower hazards for both all causes of death and CRC death. However, CRC subjects with methylation in the promoter region of MGMT showed no such correlation. Further, our results indicate that CRC patients with methylation in the promoter region of APC have better prognosis. Previous studies have suggested that hypermethylation of APC provides an important mechanism for impairing APC function and could be involved in the progression of human CRC (Hiltunen et al., 1997; Esteller et al., 2000) . In Spearman correlation analysis, no correlation among the various variables was observed when the relationship between methylation in the promoter region of APC and the cancer stage was considered. It appeared that methylation in the promoter regions of APC and MGMT was independent of the cancer stage (chi-square test, p ¼ 0.842), suggesting that the occurrence of methylation in the promoter region of APC is evenly distributed over the Dukes A to D stages. However, if the methylation occurred at the early stage of CRC tumorigenesis, it would be serve as an early stage biomarker to detect the tumorigenesis of CRC in our subjects. Thus, it is worth to further investigate the occurrence of methylation in the promoter region of APC during the development of CRC.
In our previous study, we showed that Taiwanese CRC patients present a lower frequency of germline APC mutations as compared to other ethnic groups (Chen et al., 2006) . The effects of other genetic and=or epigenetic factors-for example, methylation in the promoter regions of APC or MGMT in this study-might play an important role in the CRC development in Taiwanese subjects. If so, environmental factors, that is, frequent intake of food containing folic acid (Ryan-Harshman and Aldoori, 2007) , rather than genetic factors per se are more important in the tumorigenesis of CRC. Additional CRC families and case-control studies on the methylation in the promoter region of APC using blood samples could help delineate the association between CRC incidence and other epigenetic factors.
In this study, we also demonstrated that chemotherapy and radiotherapy did not significantly reduce the subjects' hazards for all causes of death or CRC death after adjustment for other factors (Table 3 ). Our study suggested that genetic and=or epigenetic factors might affect CRC patients' survival more prominently than both therapies. On the other hand, it is also possible that the genetic and=or epigenetic factors interact with these therapies. However, we did not observe significant interactions between both therapies and the methylation in the promoter region of APC or MGMT to the survival of CRC subjects. Besides, CRC patients harboring methylation in the promoter region of APC have significantly lower hazards for all causes of death or CRC death.
In summary, our study showed that methylation in the promoter region of APC might serve as a predictor for the prognosis of CRC patients in Taiwan. However, further study should be done in tissues harvested at different stages of CRC tumor to clarify the causal relationship of methylation and tumorigenesis.
